AbbVie Enters Global License Deal With Nxera Pharma for Experimental IBD Drug
AbbVie entered an exclusive global license deal with Nxera Pharma for an experimental inflammatory bowel disease drug.
Related stories
Samsung Fire & Marine Insurance Agrees to Acquire Remaining 60% of Canopius
Samsung Fire & Marine Insurance has entered into an agreement to acquire the remaining 60% stake in Canopius alongside funds managed by KKR. The supplied report also names KIC.
M impact | EQUITY | Nov 09, 2026, 11:04 PM UTC
Archer Aviation Reports Q3 Revenue of $5.1 Million, Sets Q4 Outlook
Archer reported a per-share loss of $0.35 for Q3 2026, versus the FactSet estimate of a $0.34 loss. Q4 2026 revenue guidance is $5.0 million to $6.0 million, above the $4.64 millio
M impact | EQUITY | Nov 09, 2026, 11:03 PM UTC
National Health Investors Reports Q3 2026 Results, Cuts FFO Guidance
National Health Investors reported normalized FFO of $1.12 per share, in line with FactSet estimates, and quarterly revenue of $113.5 million. It set 2026 normalized FFO guidance a
M impact | EQUITY | Nov 09, 2026, 11:03 PM UTC
Csquare Reports Q3 Revenue of $302.3 Million, Updates 2026 Guidance
Third-quarter revenue rose 25.6% year over year to $302.3 million. Record bookings reached $66.1 million, up for a 14th consecutive quarter sequentially; adjusted EBITDA increased
M impact | EQUITY | Nov 09, 2026, 11:03 PM UTC
Zymeworks Reports Q3 Revenue of $256.5 Million, Raises 2026 Guidance
Zymeworks reported Q3 2026 revenue of $256.5 million versus analyst expectations of $227.4 million and EPS of $2.28 versus consensus of $2.27. It raised 2026 revenue guidance to $3
M impact | EQUITY | Nov 09, 2026, 11:03 PM UTC
Plug Power Reports Third-Quarter Revenue of About $201 Million
Plug Power reported third-quarter revenue of approximately $201 million, above FactSet consensus of $198.4 million. It cited improved year-over-year gross margins and quarterly net
M impact | EQUITY | Nov 09, 2026, 11:03 PM UTC